Monitor for prospectus supplements indicating actual takedowns under the shelf, which would trigger dilution. The Baby Shelf Limitation caps near-term primary issuance at ~$7.3M, but any offering at current ~$0.69 share price would be highly dilutive to the ~34.4M shares outstanding. Watch for Nasdaq delisting risk if bid price remains below $1.00 past Jan 4, 2027.
Price Chart
Executive Summary
Quanome Technologies (formerly Lakeside Holding) filed an S-3/A shelf registration to offer up to $120M in securities, following a strategic pivot from logistics/pharma distribution to quantum AI and post-quantum cryptography. The company has a $11M market cap, negative equity trends (deficits of -$8.1M), and is at risk of Nasdaq delisting due to a sub-$1.00 bid price. The filing signals potential dilution, but the Baby Shelf Limitation caps primary offerings at ~$7.3M (one-third of $21.98M public float) per 12-month period, limiting near-term dilution risk.
Key Financial Metrics
Key Facts
- Shelf registration of up to $120,000,000 in securities (common, preferred, debt, warrants, rights, units).
- Baby Shelf Limitation applies: cannot sell >1/3 of public float (~$7.3M) in primary offerings per 12 months while public float <$75M.
- Company changed name from Lakeside Holding to Quanome Technologies and ticker from LSH to QNME on Aug 4, 2026.
- Net loss from continuing operations of $3.45M for the nine months ended March 31, 2026, vs. $1.53M loss in prior-year period.
- Revenue from continuing operations was $5.11M (nine months ended March 31, 2026), up from $0.72M in prior-year period, but the company is pivoting away from this pharma distribution business.
- Cash balance declined to $1.30M as of March 31, 2026, from $4.81M at June 30, 2025.
- Company received Nasdaq notice for non-compliance with minimum bid price ($0.6928 close on Aug 4, 2026) and has until Jan 4, 2027 to cure.
- Accumulated deficits of $8.14M as of March 31, 2026.
- Company evaluating pivot to quantum-enabled AI and post-quantum cryptography with no revenue from these activities to date.
- Cross-filing context includes a 10-Q showing deteriorating financial position and multiple prior shelf/offering filings in the last 24 months.
Financial Impact
Up to $120M shelf registered, but Baby Shelf Limitation restricts primary offerings to ~$7.3M annually. Cash burn rate suggests need for capital within 12 months.
Risk Factors
- Potential dilutive equity issuance under shelf registration
- Nasdaq delisting risk due to sub-$1.00 bid price
- Negative cash flow and declining cash reserves ($1.30M as of Mar 31, 2026)
- Unproven pivot to quantum AI/cryptography with no revenue from new business
- PRC regulatory risks for Hupan Pharmaceutical subsidiary
- Accumulated deficits of $8.14M and ongoing operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001213900-26-085359 |
| Document: ea029981301ex4-3.htm | 0001213900-26-085359 |
| Document: ea029981301ex5-1.htm | 0001213900-26-085359 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Aug 5, 2026 11w ago | 8-K | $0.5102 $0.5164 | ▲ +1.22% | ▲ +0.86% | No price |
Aug 4, 2026 12w ago | S-3/A | $0.5102 $0.5164 | ▼ −1.22% | ▼ −0.86% | No price |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers